Compare FBDT & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBDT | SRTS |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.4M | 45.6M |
| IPO Year | 2026 | 2016 |
| Metric | FBDT | SRTS |
|---|---|---|
| Price | $0.94 | $2.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | ★ 259.2K | 15.7K |
| Earning Date | 11-27-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,482,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $41.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.61 | $2.66 |
| 52 Week High | $1.25 | $5.49 |
| Indicator | FBDT | SRTS |
|---|---|---|
| Relative Strength Index (RSI) | 55.90 | 39.89 |
| Support Level | $0.86 | $2.75 |
| Resistance Level | $1.25 | $3.07 |
| Average True Range (ATR) | 0.09 | 0.14 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 69.10 | 25.00 |
First Breach Inc is an American defense technologies company focused on manufacturing match-grade ammunition components, finished ammunition, and developing unmanned aerial systems for commercial, law enforcement, and military markets. Its ammunition operations include the in-house production of brass cups, casings, projectiles, lead cores, lead wire, and completed ammunition. The company is also developing U.S.-made unmanned aerial systems incorporating robotics, intelligence, surveillance and reconnaissance (ISR), sensor, and precision manufacturing technologies for defense, homeland security, law enforcement, and commercial applications.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.